XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Quarterly Financial Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Information (Unaudited) | Quarterly Financial Information (Unaudited) The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2017 and 2016 (unaudited):
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2017 |  | September 30, 2017 |  | June 30, 2017 |  | March 31, 2017
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 7,409,214 |  |  | $ | 351,272 |  |  | $ | 16,358,316 |  |  | $ | 4,288,586 |
Revenue under collaborative research and development arrangements with affiliated entity | 226,486 |  |  | 129,133 |  |  | 176,879 |  |  | 233,330 |
Grants and miscellaneous revenue | 980,443 |  |  | 1,456,216 |  |  | 2,797,647 |  |  | 5,240,233 |
Grants and miscellaneous revenue from affiliated entity | 171,091 |  |  | 707,922 |  |  | 1,079,282 |  |  | 614,036 |
Total revenues | 8,787,234 |  |  | 2,644,543 |  |  | 20,412,124 |  |  | 10,376,185 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 24,641,124 |  |  | 25,510,239 |  |  | 23,878,751 |  |  | 24,542,504 |
General and administrative | 8,033,899 |  |  | 6,319,775 |  |  | 6,169,106 |  |  | 7,767,589 |
Gain on sale of assets | (1,000,000 | ) |  | — |  |  | — |  |  | — |
Total operating expenses | 31,675,023 |  |  | 31,830,014 |  |  | 30,047,857 |  |  | 32,310,093 |
Loss from operations | (22,887,789 | ) |  | (29,185,471 | ) |  | (9,635,733 | ) |  | (21,933,908 | )
Interest and other income, net | 509,266 |  |  | 463,346 |  |  | 300,021 |  |  | 340,341 |
Change in fair value of common stock warrants | 579,546 |  |  | 423,296 |  |  | (312,500 | ) |  | 116,477 |
Gain (Loss) from investment in affiliated entity | 292,798 |  |  | (5,835,741 | ) |  | 169,096 |  |  | (1,608,817 | )
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (21,506,179 | ) |  | $ | (34,134,570 | ) |  | $ | (9,479,116 | ) |  | $ | (23,085,907 | )
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders |  |  |  |  |  |  |
Basic | $ | (0.24 | ) |  | $ | (0.39 | ) |  | $ | (0.13 | ) |  | $ | (0.31 | )
Diluted | $ | (0.24 | ) |  | $ | (0.40 | ) |  | $ | (0.13 | ) |  | $ | (0.31 | )
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2016 |  | September 30, 2016 |  | June 30, 2016 |  | March 31, 2016
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 476,586 |  |  | $ | 2,327,316 |  |  | $ | 1,889,988 |  |  | $ | 1,796,857 |
Revenue under collaborative research and development arrangements with affiliated entity | 189,278 |  |  | 574,596 |  |  | 499,720 |  |  | 137,000 |
Grants and miscellaneous revenue | 7,735,428 |  |  | 9,410,648 |  |  | 3,814,083 |  |  | 6,176,298 |
Grants and miscellaneous revenue from affiliated entity | 112,660 |  |  | 227,903 |  |  | — |  |  | — |
Total revenues | 8,513,952 |  |  | 12,540,463 |  |  | 6,203,791 |  |  | 8,110,155 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 23,911,731 |  |  | 26,980,343 |  |  | 19,630,801 |  |  | 18,189,160 |
General and administrative | 6,965,517 |  |  | 5,755,603 |  |  | 5,799,530 |  |  | 5,371,613 |
Gain on sale of assets | — |  |  | — |  |  | (1,000,000 | ) |  | — |
Total operating expenses | 30,877,248 |  |  | 32,735,946 |  |  | 24,430,331 |  |  | 23,560,773 |
Loss from operations | (22,363,296 | ) |  | (20,195,483 | ) |  | (18,226,540 | ) |  | (15,450,618 | )
Interest and other income, net | 191,460 |  |  | 391,596 |  |  | 341,131 |  |  | 333,070 |
Change in fair value of common stock warrants | 644,888 |  |  | 2,690 |  |  | (113,775 | ) |  | (406,249 | )
Gain (Loss) from investment in affiliated entity | (4,706,522 | ) |  | (958,141 | ) |  | (705,527 | ) |  | 7,480,977 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (26,233,470 | ) |  | $ | (20,759,338 | ) |  | $ | (18,704,711 | ) |  | $ | (8,042,820 | )
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders |  |  |  |  |  |  |
Basic | $ | (0.35 | ) |  | $ | (0.28 | ) |  | $ | (0.26 | ) |  | $ | (0.11 | )
Diluted | $ | (0.36 | ) |  | $ | (0.28 | ) |  | $ | (0.26 | ) |  | $ | (0.11 | )

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration